Clinical and economic aspects of risperidone treatment in adults with mental retardation and behavioral disturbance. 1996

R S Lott, and J M Kerrick, and S A Cohen
Pharmacy Department, Fircrest, Seattle, WA 98155, USA.

Risperidone, in conjunction with behavioral interventions, was used to reduce aggression and assault, self-injury, and property destruction in 33 institutionalized adults with mental retardation. Target behavior frequencies, global assessments by staff, wages earned by patients, and the institution's costs for assault-related injury to staff and lost work time were evaluated before and after initiation of risperidone treatment. Risperidone (1-8 mg/day) was associated with a 50 percent or greater reduction in at least one target behavior frequency in 61 percent of patients. After 6 months of treatment, 85 percent of patients were rated "improved" and 15 percent were rated "unchanged." Treated patients' wage earnings increased by 37 percent. The number of staff work days lost because of assault by treated patients decreased from 444 during the 6 months before initiation of risperidone to 29 during the 6 months after initiation. Sedation, pseudoparkinsonism, possible akathisia, and weight gain were noted in 9-12 percent of patients. No patients were withdrawn from risperidone because of intolerable side effects or lack of efficacy. The results of this evaluation suggest that risperidone is effective and well tolerated in this population.

UI MeSH Term Description Entries
D008297 Male Males
D008607 Intellectual Disability Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual has an intellectual disability. IQ scores between 70 and 79 are in the borderline range. Scores below 67 are in the disabled range. (from Joynt, Clinical Neurology, 1992, Ch55, p28) Disability, Intellectual,Idiocy,Mental Retardation,Retardation, Mental,Deficiency, Mental,Intellectual Development Disorder,Mental Deficiency,Mental Retardation, Psychosocial,Deficiencies, Mental,Development Disorder, Intellectual,Development Disorders, Intellectual,Disabilities, Intellectual,Disorder, Intellectual Development,Disorders, Intellectual Development,Intellectual Development Disorders,Intellectual Disabilities,Mental Deficiencies,Mental Retardations, Psychosocial,Psychosocial Mental Retardation,Psychosocial Mental Retardations,Retardation, Psychosocial Mental,Retardations, Psychosocial Mental
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001523 Mental Disorders Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function. Mental Illness,Psychiatric Diseases,Psychiatric Disorders,Psychiatric Illness,Behavior Disorders,Diagnosis, Psychiatric,Mental Disorders, Severe,Psychiatric Diagnosis,Illness, Mental,Mental Disorder,Mental Disorder, Severe,Mental Illnesses,Psychiatric Disease,Psychiatric Disorder,Psychiatric Illnesses,Severe Mental Disorder,Severe Mental Disorders
D018967 Risperidone A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA. R-64,766,R-64766,Risperdal Consta,Risperidal,Consta, Risperdal,R 64,766,R 64766,R64,766,R64766

Related Publications

R S Lott, and J M Kerrick, and S A Cohen
January 2000, Mental retardation and developmental disabilities research reviews,
R S Lott, and J M Kerrick, and S A Cohen
April 2006, Journal of autism and developmental disorders,
R S Lott, and J M Kerrick, and S A Cohen
January 2000, Actas espanolas de psiquiatria,
R S Lott, and J M Kerrick, and S A Cohen
January 1968, Shinkei kenkyu no shimpo. Advances in neurological sciences,
R S Lott, and J M Kerrick, and S A Cohen
June 1970, Wisconsin medical journal,
R S Lott, and J M Kerrick, and S A Cohen
September 1965, American journal of mental deficiency,
R S Lott, and J M Kerrick, and S A Cohen
July 1990, No to hattatsu = Brain and development,
R S Lott, and J M Kerrick, and S A Cohen
February 1973, Pediatric clinics of North America,
R S Lott, and J M Kerrick, and S A Cohen
January 2004, Public health reports (Washington, D.C. : 1974),
Copied contents to your clipboard!